AbCellera, Silence and InduPro secure major funding rounds as AbCellera completes $200M share sale

Vancouver based biotech AbCellera announced a $200 million share offering after meeting its efficacy targets in a Phase 2 hot flashes trial. The capital raise follows the company achieving its predefined endpoints.

Silence and InduPro also reported closing sizable financing rounds, adding to the momentum in the sector.

The new funds are expected to support further development of their pipelines and expand commercial activities.

Investors view the financing as a vote of confidence in the companies' therapeutic programs and growth prospects.